EP 1771461 A2 20070411 - NOVEL 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES USED IN THE FORM OF INHIBITORS OF 17BETA-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 1
Title (en)
NOVEL 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES USED IN THE FORM OF INHIBITORS OF 17BETA-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 1
Title (de)
NEUE 2-SUBSTITUIERTE ESTRA-1,3,5(10)-TRIEN-17-ONE ALS INHIBITOREN DER 17BETA-HYDROXY-STEROIDDEHYDROGENASE TYP 1
Title (fr)
NOUVELLES OESTRA-1,3,5(10)-TRIENE-17-ONES 2-SUBSTITUEES, UTILISEES COMME INHIBITEURS DE LA 17BETA-HYDROXYSTEROIDE-DEHYDROGENASE DE TYPE 1
Publication
Application
Priority
- EP 2005007315 W 20050704
- DE 102004032674 A 20040702
Abstract (en)
[origin: WO2006003013A2] The invention relates to novel 2-substituted estra-1,3,5(10)-trien-17-ones of formula (I), wherein R<SUP>2 </SUP>is an C<SUB>1</SUB>-C<SUB>8</SUB> alkyl saturated or unsaturated group, an C<SUB>1</SUB>-C<SUB>5</SUB>-alkyloxy group, an aralkyl- or alkylaryl rest, an -O-C<SUB>n</SUB>F<SUB>m</SUB>H<SUB>o</SUB> rest, wherein n=1,2,3,4,5 or 6, m=1 and m = 2n+1, or a CH<SUB>2</SUB>XY group in which X is an oxygen atom and Y is an alkyl rest containing 1 to 4 carbon atoms, a halogen atom and a nitrile group, R<SUP>13 </SUP>is a hydrogen atom<SUP/>or a methyl group, R<SUB>16</SUB> is a hydrogen or fluorine atom, Z is an oxygen or sulfur atom, each R<SUP>4</SUP> and R<SUP>6</SUP> independently of each other represents a or ß hydrogen atom, an C<SUB>1</SUB>-C<SUB>5 </SUB>alkyl, C<SUB>1</SUB>-C<SUB>5</SUB>-alkyloxy, C<SUB>1</SUB>-C<SUB>5</SUB>-acyl or hydroxy group or an aralkyl- or alkylaryl rest, R<SUB>3</SUB> and R<SUB>4 </SUB>represent together an oxygen atom, R<SUB>5</SUB> and R<SUB>6</SUB> represent together an oxygen atom, each R<SUP>7</SUP> and R<SUP>8</SUP> represents a hydrogen atom or together an oxygen atom, each R<SUP>7</SUP> and R<SUP>8</SUP> represents a hydrogen atom or together a CH<SUB>2</SUB> group. Pharmaceutically acceptable salts of said compounds, the production and use thereof in the form of drags which are usable for preventing and treating estrogen-dependent diseases and are influenced by inhibiting 17ß-hydroxysteroiddehydrogenase of type 1 are also disclosed.
IPC 8 full level
C07J 1/00 (2006.01); A61K 31/566 (2006.01); A61P 5/32 (2006.01); C07J 31/00 (2006.01); C07J 41/00 (2006.01); C07J 53/00 (2006.01)
CPC (source: EP)
A61K 31/565 (2013.01); A61K 45/06 (2013.01); A61P 5/30 (2017.12); A61P 5/32 (2017.12); A61P 15/08 (2017.12); A61P 35/00 (2017.12); A61P 43/00 (2017.12); C07J 1/0059 (2013.01); C07J 31/003 (2013.01); C07J 41/0094 (2013.01); C07J 53/004 (2013.01)
Citation (search report)
See references of WO 2006003013A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA HR MK YU
DOCDB simple family (publication)
DE 102004032674 A1 20060126; EP 1771461 A2 20070411; JP 2008504338 A 20080214; WO 2006003013 A2 20060112; WO 2006003013 A3 20060622; WO 2006003013 B1 20060831
DOCDB simple family (application)
DE 102004032674 A 20040702; EP 05767936 A 20050704; EP 2005007315 W 20050704; JP 2007518558 A 20050704